Advertisement
U.S. markets open in 9 hours 28 minutes
  • S&P Futures

    5,204.00
    -10.75 (-0.21%)
     
  • Dow Futures

    39,183.00
    -40.00 (-0.10%)
     
  • Nasdaq Futures

    18,162.75
    -68.75 (-0.38%)
     
  • Russell 2000 Futures

    2,045.10
    -4.70 (-0.23%)
     
  • Crude Oil

    82.52
    -0.20 (-0.24%)
     
  • Gold

    2,163.80
    -0.50 (-0.02%)
     
  • Silver

    25.30
    +0.03 (+0.12%)
     
  • EUR/USD

    1.0878
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2724
    -0.0005 (-0.04%)
     
  • USD/JPY

    149.7250
    +0.6270 (+0.42%)
     
  • Bitcoin USD

    65,953.31
    -1,938.78 (-2.86%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,830.01
    +89.57 (+0.23%)
     

Acasti Pharma Gains Ahead Of Expected Phase II Results

Acasti Pharma Inc (NASDAQ: ACST) gained more than 4 percent Thursday ahead of the expected release of complete data from Phase II trials of its lead drug candidate.

With a market capitalization of $41 million, shares of the Laval, Quebec-based company changed hands recently at
$0.551, up $0.024.

Acasti, which is developing medicine for blood disorders using oil from plankton, said last month that it expects to obtain complete data from the trial by the end of February.

Acasti expects to meet with U.S. regulators concerning the data during the first quarter ending May 31, and obtain "a clearer picture on the projected timeline" for a Phase III trial of the product, called CaPre.

The product is the company's only drug candidate and Acasti hopes to market it for treatment of hypertriglyceridemia, a condition which can lead to cardiovascular disease.

Acasti received notice November 11 that failed to meet the Nasdaq minimum $1 bid listing requirement and that it had 180 days to comply.

See more from Benzinga

© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement